MedPath

Non-alcoholic Fatty Liver Disease in Low Birth Weight Individuals

Not Applicable
Not yet recruiting
Conditions
NAFLD
Interventions
Other: No intervention
Behavioral: Caloric restriction intervention
Registration Number
NCT05842850
Lead Sponsor
Steno Diabetes Center Copenhagen
Brief Summary

The investigators will conduct a proof-of-principle deep phenotyping 4-weeks caloric restriction intervention study in low birth weight (LBW) subjects with NAFLD and normal birth weight (NBW) controls. Furthermore, the investigators will provide extended in-depth mechanistic insight into the role of impaired subcutaneous adipose tissue (SAT) expandability in ectopic fat deposition in LBW subjects in LBW individuals with and without NAFLD.

Detailed Description

An adverse fetal environment characterized by low birth weight (LBW) plays a key role in the development of type 2 diabetes (T2D). The investigators recently demonstrated a 3-fold increase in liver fat in 26 early middle-aged LBW compared to 22 normal birth weight (NBW) men, and 20% of the LBW - but none of the normal birth weight (NBW) - men had previously unknown non-alcoholic fatty liver disease (NAFLD). The investigators hypothesize that ectopic fat deposition and NAFLD is among the earliest disease manifestations and on the critical path to the development of more severe cardiometabolic disease in LBW. The investigators furthermore hypothesize, that LBW individuals exhibit ectopic liver fat due to reduced capacity to store fat in the subcutaneous adipose tissue (SAT) depot, and that early detection and subsequent intensive caloric restriction, in middle-aged LBW individuals with overt NAFLD, may represent a targeted and highly efficient way forward to prevent more severe cardiometabolic disease manifestations in LBW subjects. To further explore the recent findings, the investigators aim to perform an extended nested case-control screening study for NAFLD in 250 early middle-aged non-obese LBW men and women, and subsequently to conduct a deep-phenotyping, proof-of-principle 4 week time-restricted eating (TRE) intervention study in 12 LBW subjects with NAFLD including measures of hepatic fat content, glucose, insulin and lipid metabolism, as well as 24h metabolic profiles using respiratory chambers. Finally, the investigators will provide extended in-depth mechanistic insight into transcriptional, epigenetic as well as functional SAT and preadipocyte perturbations underlying impaired SAT expandability in LBW individuals with and without NAFLD and NBW controls studied before and after different dietary interventions including TRE and high carbohydrate overfeeding.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
24
Inclusion Criteria
  • LBW subjects with NAFLD (liver fat content ≥5% liver fat content verified on MRS)
  • Gender- and body mass index-matched NBW controls without NAFLD
  • Born at term (weeks 39-41)
Exclusion Criteria
  • BMI<18.5 and BMI>30 kg/m2
  • Family history of diabetes (siblings, parent, and grandparents)
  • Disease/medication known to affect primary outcome
  • Self-reported high physical activity level
  • Alcohol intake above general recommendations.
  • Metabolic/liver disease
  • Weight gain/loss of >3 kg within the past 6 months

Study & Design

Study Type
INTERVENTIONAL
Study Design
SEQUENTIAL
Arm && Interventions
GroupInterventionDescription
NBW controls without NAFLDNo interventionAge-, gender- and body mass index-matched NBW controls without NAFLD
LBW individuals with NAFLDCaloric restriction interventionLBW individuals with NAFLD
Primary Outcome Measures
NameTimeMethod
Liver fat contentChange from baseline in liver fat content at 4 weeks

Validation by Magnetic resonance spectroscopy (MRS)

Secondary Outcome Measures
NameTimeMethod
Liver fibrosisBaseline and after 4 weeks

Liver elastography (FibroScan)

Fat turnover rateBaseline and after 4 weeks

Stable isotope dilution techniques

Urea turnover rateBaseline and after 4 weeks

Stable isotope dilution techniques

Beta-cell functionBaseline and after 4 weeks

Intravenous glucose tolerance test

Whole-body insulin sensitivityBaseline and after 4 weeks

Stepwise hyperinsulinemic-euglycemic clamp

24-hour energy metabolismBaseline and after 4 weeks

Indirect calorimetry in respiratory chamber

Glucose turnover rateBaseline and after 4 weeks

Stable isotope dilution technique

Body compositionBaseline and after 4 weeks

DEXA scan

© Copyright 2025. All Rights Reserved by MedPath